US 7183105B2
· Sabbadini et al.
· 2007
[cited by applicant]
US 8591862B2
· Brahmbhatt et al.
· 2013
[cited by applicant]
US 9220724B2
· Reid
· 2015
[cited by applicant]
US 9566321B2
· Giacalone
· 2017
[cited by applicant]
US 9730897B2
· Brahmbhatt et al.
· 2017
[cited by applicant]
US 9731011B2
· Brahmbhatt
· 2017
[cited by examiner]
US 20160340439A1
· Engleman et al.
· 2016
[cited by applicant]
CN 104837506A
· 2015
[cited by applicant]
CN 105658233A
· 2016
[cited by applicant]
CN 106170299A
· 2016
[cited by applicant]
JP 2009538337A
· 2009
[cited by applicant]
JP 2010523724A
· 2010
[cited by applicant]
JP 2012514476A
· 2012
[cited by applicant]
WO WO2000067776
· 2000
[cited by applicant]
WO WO2003033519A2
· 2003
[cited by applicant]
WO WO2004113507A1
· 2004
[cited by applicant]
WO WO2005056749A2
· 2005
[cited by applicant]
WO WO2005079854A1
· 2005
[cited by applicant]
WO WO2007137258A2
· 2007
[cited by applicant]
WO WO2008128207A1
· 2008
[cited by applicant]
WO WO2009027830A2
· 2009
[cited by applicant]
WO WO2010081026A1
· 2010
[cited by applicant]
WO WO2011057003A2
· 2011
[cited by examiner]
WO WO2015049589A1
· 2015
[cited by applicant]
WO WO2017180650A1
· 2017
[cited by applicant]
Vitale et al. (Annals of Surgery, 246, 2, 2007, 259-268).
[cited by examiner]
MacDiarmid et al. (Nature Biotechnology vol. 27 No. 7 Jul. 2009, 643-654).
[cited by examiner]
Nagaraj et al. (International Immunology, vol. 18, No. 8, pp. 1279-1283).
[cited by examiner]
Martin et al. (MABS 2018, vol. 10, No. 2, 210-221).
[cited by examiner]
Cavlar et al. (Immunology and Cell Biology (2012) 90, 474-482).
[cited by examiner]
Ahmadzadehfar et al., “Radioembolization of liver tumors with yttrium-90 microspheres,”
[cited by applicant]
Ablasser et al., “RIG-I Dependent Sensing of Poly9dA-dT) via the Induction of an RNA Polymerase III Transcribed RNA Intermediate,”
[cited by applicant]
Ablasser et al., “Cell Intrinsic Immunity Spreads to Bystander Cells via the Intercellular Transfer of cGAMP,”
[cited by applicant]
Adamus et al., “The Revival of CpG Oligonucleotide-based Cancer Immunotherapies,”
[cited by applicant]
Ahmadzadehfar et al., “Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer,” Oncotarget. 2016;7(11):12477-12488.
[cited by applicant]
Alexopoulou et al., “Recognition of Double-Stranted RNA and Activation of NF-kappaB by Toll-like Receptor 3,”
[cited by applicant]
Anguille et al., “Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy,”
[cited by applicant]
Barber et al., “Inmate Immune DNA Sensing Pathways: Sting, Aimii and the Regulation of Interferon Production and Inflammatory Responses,”
[cited by applicant]
Bernardini et al., Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases,
[cited by applicant]
Alzahrani, et al., “Diagnostic value of recombinant human thyrotropin-stimulated 123I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer,”
[cited by applicant]
Andersson, et al., “Large-scale synthesis of peptides,”
[cited by applicant]
Belardelli et al., “Cytokines as a Link between Innate and Adaptive Antitumor Immunity,”
[cited by applicant]
Debinski, et al., “Molecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-associated Cancer/Testis Antigen,”
[cited by applicant]
Goh, et al., “Endocytosis of Receptor Tyrosine Kinases,”
[cited by applicant]
Oh, et al., siRNA Delivery Systems for Cancer Treatment,
[cited by applicant]
Kota et al., “Therapeutic Delivery of miR-26a Inhibits Cancer Cell Proliferation and Induces Tumor-Specific Apoptosis,”
[cited by applicant]
Wykosky et al., “Interleukin-13 Receptor α2, EphA2, and Fos-Related Antigen 1 as Molecular Denominators of High-Grade Astrocytomas and Specific Targets for Combinatorial Therapy,”
[cited by applicant]
Lemmon, et al., “Cell Signaling by Receptor-Tyrosine Kinases,”
[cited by applicant]
Tanpure, et al., “Synthesis of Structurally Diverse Benzosuberene Analogues and their Biological Evaluation as Anti-Cancer Agents,”
[cited by applicant]
MacDiarmid, et al., “Bacterially Derived 400 nm Particles for Encapsulation and Cancer Cell Targeting of Chemotherapeutics,”
[cited by applicant]
MacDiarmid, et al., “Bacterially-Derived Nanocells for Tumor-Targeted Delivery of Chemotherapeutics and Cell Cycle Inhibitors,”
[cited by applicant]
Rice, et al., “The Next Generation of Positron Emission Tomography Radiopharmaceuticals in Oncology,”
[cited by applicant]
Khalil, et al., “Many Human Large Intergenic Noncoding RNAs Associate with chromatin-modifying complexes and affect gene expression,” PNAS, vol. 106, No. 28, pp. 11667-11672 (Jul. 2009).
[cited by applicant]
Duxbury, et al., “Systemic siRNA-Mediated Gene Silencing a New Approach to Targeted Therapy of Cancer,”
[cited by applicant]
Debinski, et al., “Expression of a Restrictive Receptor for Interleukin 13 is Associated with Glial Transformation,”
[cited by applicant]
Dasilva, et al., “HER3 and downstream pathways are involved in colonization of Brain Metastases from Breast Cancer,”
[cited by applicant]
Chu et al., “Translation Repression in Human Cells by MicroRNA-Induced Gene Silencing Requires RCK/p54,”
[cited by applicant]
Caravella, et al., “Design of next-generation protein therapeutics,”
[cited by applicant]
MacDiarmid, et al., “Sequential Treatment of Drug-Resistant Tumors with Targeted Minicells containing SIRNA or a Cytotoxic Drug,”
[cited by applicant]
Duan, et al., “Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) Expression by Small Interfering RNA and Reversal of Paclitaxel Resistance in Human Ovarian Cancer Cells,” Molecular Cancer Therapies, vol. 3, No. 7, pp. 833-838…
[cited by applicant]
De Boer et al., “Roles of MinC and MinD in the Site-Specific Septation Block Mediated by the MinCDE System of
[cited by applicant]
Okada, et al., “Cytoplasmic Axial Filaments in
[cited by applicant]
Nieth, et al., Modulation of the Classical Multidrug Resistance (MDR) Phenotype by RNA Interference (RNAi),
[cited by applicant]
Reeve, et al., “bacteriophage SPO1-Induced Macromolecular Synthesis in Minicells of bacillus subtilis,”
[cited by applicant]
Raskin, et al., “MinDE-Dependent Pole-to-Pole Oscillation of Division Inhibitor MinC in
[cited by applicant]
Caplen, et al., “Short Interfering RNA (siRNA)—Mediated RNA Interference (RNAi) in Human Cells,”
[cited by applicant]
Britton, et al., “Characterization of a prokaryotic SMC protein involved in chromosome partitioning,”
[cited by applicant]
Caplen, “RNAi as Gene Therapy Approach,”
[cited by applicant]
Sioud, “Therapeutic siRNAs,”
[cited by applicant]
Stewart, et al., “Genetic and Morphological Characterization of an
[cited by applicant]
Hiraga, et al., “Chromosome Partitioning in
[cited by applicant]
Harry, “Bacterial Cell Divisional: Regulating Z-ring formation,”
[cited by applicant]
Hu et al., “Topological Regulation of Cell Divisional in
[cited by applicant]
Quintieri, et al., “Formation and Antitumor Activity of PNU-159682, A Major Metabolite of Nemorubicin in Human Liver Microsomes,”
[cited by applicant]
Iftode, et al., “Replication Protein A (RPA): the Eukaryotic SSB,”
[cited by applicant]
Gregory, et al., Methods in Molecular Biology, vol. 342, pp. 33-47 ( Apr. 2006).[Abstract].
[cited by applicant]
Hershey, “IL-13 Receptors and Signaling Pathways: an Evolving web,”
[cited by applicant]
International Search Report and Written Opinion issued in International Patent Application No. PCT/IB2019/056259, dated Dec. 24, 2019.
[cited by applicant]
Macdiarmid, et al., “Minicells: Versatile Vectors for Targeted Drug or si/shRNA Cancer Therapy,” Current Opinion in Biotechnology, vol. 22, pp. 909-916 (2011).
[cited by applicant]
Ablasser, et al., “cGAS Produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING,”
[cited by applicant]
Frederick Allen and Juliana Bobanga, et al., “CCL3 augments tumor rejection and enhances CD8C T cell infiltration through NK and CD103C dendritic cell recruitment via IFNγ,”
[cited by applicant]
Aduro Biotech Inc., Novartis Pharmaceuticals,
[cited by applicant]
Birkholz, et al., “The Alpha and Omega of Galactosylceramides in T Cell Immune Function,”
[cited by applicant]
Bredel, “Anticancer drug resistance in primary human brain tumors,” brain Res. Rev., 35, pp. 161-204 (2001).
[cited by applicant]
Brody et al., “In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study,”
[cited by applicant]
Bürckstümmer, et al., “An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome,”
[cited by applicant]
Burger, et al., “Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells,”
[cited by applicant]
Carreno et al., “Synthetic Glycolipid Activators of Natural Killer T Cells as Immunotherapeutic Agents,”
[cited by applicant]
Caskey, et al., “Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans,”
[cited by applicant]
Cauwels, et al., “Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments,”
[cited by applicant]
Chatalic, et al., “Radiopeptides for imaging and therapy: a radiant future,” J Nucl Med., vol. 56, pp. 1809-1812 (2015).
[cited by applicant]
Chen et al., “Reversal of Drug Resistance Mediated By Multidrug Resistance Protein (MRP) 1 By Dual Effects of Agosterol a on MRP1 Function”, Int. J. Cancer: 93, 107-113 (2001).
[cited by applicant]
Chikuma et al., “Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy,”
[cited by applicant]
Chiu et al., RNA Polymerase III Detects Cytosolic DNA and Induces Type-1 Interferons Through the RIG-I Pathway,
[cited by applicant]
Civril et al., “Structural mechanism of cytosolic DNA sensing by cGAS,” vol. 498, pp. 332-337 (2013).
[cited by applicant]
Clark-Curtiss and Curtiss, “Analysis of Recombinant DNA Using
[cited by applicant]
Colonna, et al., “Plasmacytoid Dendritic Cells in Immunity,”
[cited by applicant]
Corrales, et al., “Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity,”
[cited by applicant]
Cory, et al., “Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture,” Cancer Commun., vol. 3, No. 7, pp. 207-212 (1991).
[cited by applicant]
D'Aloia et al., “CAR-T Cells: The Long and Winding Road to Solid Tumors,”
[cited by applicant]
D'Angiolella et al., “Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA Repair,” Cell, 149:1023-34 (2012).
[cited by applicant]
Deutscher, “Phage Display in Molecular Imaging and Diagnosis of Cancer,” Chem Rev., vol. 110, pp. 3196-3211 (2010).
[cited by applicant]
Dine et al., “Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer,”
[cited by applicant]
Dobbs et al., “STING activation by translocation from the ER is associated with infection and autoinflammatory disease,” Cell Host Microbe, 18(2): 15-24 (2015).
[cited by applicant]
Dong et al., “CD86+ /CD206+, Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis,” International journal of molecular sciences 17, 320 (2016), 12 pages.
[cited by applicant]
Dowling et al., “The Ultra-Potent and Selective TLR8 Agonist VTX-294 Activates Human Newborn and Adult Leukocytes,” PLoS One, 8:e58164 (2013), 11 pages.
[cited by applicant]
Dredge et al., “Adjuvants and the promotion of Th1-type cytokines in Tumour immunotherapy,” Cancer immunology, immunotherapy: CII 51, pp. 521-531 (2002).
[cited by applicant]
Dynavax Technologies Corporation. Study of SD-101 in Combination with Localized Low-dose Radiation in Patients with Untreated Low-grade B-cell Lymphoma. 2016. ClinicalTrials.gov [Internet]. Bethesda (MD): National Libra…
[cited by applicant]
Zitvogel et al., “Type I IFNs and Anticancer Therapies,” Nature reviews Immunology 15, pp. 405-414 (2015).
[cited by applicant]
Ziegler-Heitbrock et al., “Toward a Refined Definition of Monocyte Subsets,” Frontiers in Immunology 4, 23 (2013).
[cited by applicant]
Zibert et al., CCL3/MIP-1α is a Potent Immunostimulator When Coexpressed with Interleukin-2 or Granulocyte-Macrophage Colony-Stimulating Factor in a Leukemia/Lymphoma Vaccine Human Gene Therapy 15, pp. 21-34 (2004).
[cited by applicant]
Zhang et al., “The hellcase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells,” Nat. Immunol., 12, pp. 959-965 (2011b).
[cited by applicant]
Zhang et al., “Cutting Edge: Ku70 is a Novel Cytosolic DNA Sensor That Induces Type III Rather Than Type I IFN,” J. Immunol., 186:4541-4545 (2011a).
[cited by applicant]
Yuan et al., “Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression,” Scientific reports 5, 14273 (2015).
[cited by applicant]
Yi et al., Single Nucleotide Polymorphisms of Human STING Can Affect Innate Immune Response to Cyclic Dinucleotides
[cited by applicant]
Yang et al., “The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a β-catenin-dependent pathway,”
[cited by applicant]
Yang et al., “A Novel tumor-homing peptide specifically targeting metastasis,” Clin Cancer Res., vol. 14, pp. 5494-5502 (2008).
[cited by applicant]
Yague et al., “Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1,” Gene Ther., 11, pp. 1170-1174 (2004).
[cited by applicant]
Emens et al., “Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape,” European Journal of Cancer 81, pp. 116-129 (2017).
[cited by applicant]
Erathodiyil N, Ying JY. Functionalization of inorganic nanoparticles for bioimaging applications. Acc Chem Res., vol. 44, pp. 925-935 (2011).
[cited by applicant]
International Preliminary Report on Patentability issued in International Patent Application No. PCT/IB2019/056259, dated Jan. 26, 2021.
[cited by applicant]
Farkona, et al., “Cancer immunotherapy: the beginning of the end of cancer?,”
[cited by applicant]
Fang, et al., “NK cell-based immunotherapy for cancer,”
[cited by applicant]
Ferlazzo et al., “NK Cell Compartments and Their Activation by Dendritic Cells1,”
[cited by applicant]
Fernandes-Alnemri et al., “AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA,” Nature, vol. 458, pp. 509-513 (2009).
[cited by applicant]
Field et al., “Inducers of Interferon and Host Resistance, II. Multistranded Synthetic Polynucleotide Comlexes,” Proc. Natl Acad. Sci. USA, 58: pp. 1004-1010 (1967).
[cited by applicant]
Fitzgerald-Bocarsly et al., “The role of type I Interferon Production by Dendritic Cells in Host Defense,”
[cited by applicant]
Fu, et al., “STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade,”
[cited by applicant]
Fukuda, “Chemical labeling of carbohydrates by oxidation and sodium borohydride reduction,” Curr Protoc. Mol. Biol., pp. 17.5.1-17.5.8: Supplement 26 (1994).
[cited by applicant]
Gao et al., “In vivo Cancer Targeting and Imaging with Semiconductor Quantum Dots,”
[cited by applicant]
Gao et al., Cyclic GMP-AMP Synthase is an Innate Immune Sensor of HIV and Other Retroviruses,
[cited by applicant]
Gao et al., “Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by VA-Activated Cyclic GMP-AMP Synthase,”
[cited by applicant]
Gerard SK, Cavalieri RR. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med. 2002;27(1):1-8.
[cited by applicant]
Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
[cited by applicant]
Gitlin et al., “Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus,”
[cited by applicant]
Gray, et al., “Combinatorial Peptide Libraries: Mining for Cell-Binding Peptides,”
[cited by applicant]
Hobbs et al., “Regulation of Transport Pathways in Tumor Vessels: Role of Tumor Type and Microenvironment,”
[cited by applicant]
Hansen, et al., “Listeria monocytogenes induces IFNβ Expression through an IFI16-, CGAS- and STING-dependent Pathway,”
[cited by applicant]
Holman, et al., “Single-photon emission computed tomography (SPECT): applications and potential,” JAMA, vol. 263, No. 4, pp. 561-564 (1990).
[cited by applicant]
Hornung et al., “AIM2 Recognizes Cytosolic dsDNA and forms a Caspase-1 Activating Inflammasome with ASC,”
[cited by applicant]
Igarashi, et al., “Vasoactive intestinal peptide (VIP) and VIP receptors-elucidation of structure and function for therapeutic applications,” Int J Clin Med., vol. 2, pp. 500-508 (2011).
[cited by applicant]
Jarboe, et al., Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies,
[cited by applicant]
Jenkins et al., “Mechanisms of Resistance to Immune Checkpoint Inhibitors,”
[cited by applicant]
Jung et al., “Dendritic Cell-Based Immunotherapy for Solid Tumors,”
[cited by applicant]
Kao et al., “A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma,”
[cited by applicant]
Kawai, et al., “The role of pattern-recognition receptors in innate immunity: update on Toll-like Receptors,”
[cited by applicant]
Kim, et al., “Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells,” PNAS, vol. 107, No. 34, pp. 15181-15186 (Aug. 2010).
[cited by applicant]
Kramer-Marek G, et al., “The role of nuclear medicine in modern therapy of cancer,” Tumour Biol. 2012;33(3), pp. 629-640.
[cited by applicant]
Xia et al., “Sox2 functions as a sequence-specific DNA sensor in neutrophils to initiate innate immunity against microbial infection,”
[cited by applicant]
Wu, et al., “Cyclic-GMP-AMP is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA,” Science, vol. 339, pp. 826-830 (2013).
[cited by applicant]
Whittle, et al., “First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma,” Journ. of Clinical Neuroscience, vol. 22, pp. 1889-1894 (2015).
[cited by applicant]
White, et al., “Suppression of apoptosis: role in cell growth and neoplasia,”
[cited by applicant]
Walrand, et al., “The impact of image reconstruction bias on PET/CT
[cited by applicant]
Sharpe, “Introduction to Checkpoint Inhibitors and Cancer Immunotherapy,”
[cited by applicant]
Kranzusch et al., “Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity,”
[cited by applicant]
Krieg et al., “CpG Motifs in Bacterial DNA Trigger Direct B-cell Activation,”
[cited by applicant]
Kwekkeboom et al., “Treatment with the radiolabeled somatostatin analog [
[cited by applicant]
Landskron et al., “Chronic Inflammation and Cytokines in the Tumor Microenvironment,” Journal of Immunology Research 2014, 149185, 20 pages (2014).
[cited by applicant]
Lee et al., “Cytokines in Cancer Immunotherapy,”
[cited by applicant]
Leung, et al., “When your cap matters: Structural insights into self vs non-self recognition of 5′ RNA by immunomodulatory host proteins,” ,
[cited by applicant]
Li et al., “Pivotal Roles of cGAS-cGAMP Signaling in Antiviral Defense and Immune Adjuvant Effects,”
[cited by applicant]
Liu et al., “Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 Activation,”
[cited by applicant]
Lu et al., “The Structural Basis of 50 Triphosphate Double-Stranded RNA Recognition by Rig-I C-Terminal Domain,”
[cited by applicant]
Ma et al., “Positioning of the MinE binding site on the MinD surface suggests a plausible mechanism for activation of the
[cited by applicant]
MacDiarmid et al., “Targeted Doxorubicin Delivery to Brain Tumors viaMinicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model,”
[cited by applicant]
Majkowska et al., “Complexes of low energy beta emitters
[cited by applicant]
McWhirter et al., “A Host Type I Interferon Response is Induced by Cytosolic Sensing of the Bacterial Second Messenger Cyclic-di-GMP,”
[cited by applicant]
Mellman et al., “Cancer Immunotherapy Comes of Age,”
[cited by applicant]
Morvan et al., “NK cells and cancer: you can teach innate cells new tricks,”
[cited by applicant]
Muller, et al., “A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for a- and b2-Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative,”
[cited by applicant]
Oiseth et al., “Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead,”
[cited by applicant]
Orzalli et al., “Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein,”
[cited by applicant]
Reid et al., “Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma,” Annals of Oncology, Official Journal of the European Society for Medical Oncology, vol. 24, pp. 3128-3135 (2…
[cited by applicant]
Rezvani et al., “Engineering Natural Killer Cells for Cancer Immunotherapy,”
[cited by applicant]
Sawa-Wejksza et al., “
[cited by applicant]
Silver, et al., “Prostate-specific membrane antigen expression in normal and malignant human tissues,”
[cited by applicant]
Schoggins et al., “Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity,”
[cited by applicant]
Unterholzner et al., “IFI16 is an Innate Immune Sensor for Intracellular DNA,” Nat. Immunol., vol. 11, pp. 997-1004 (2010).
[cited by applicant]
Wang, et al., “Structural and functional insights into pattern recognition by the innate immune receptor RIG-1,”
[cited by applicant]
Staudacher, et al., “Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?,”
[cited by applicant]
Wang et al., “The E3 Ubiquitin Ligase AMFR and INSIG1 Bridge the Activation of TBK1 Kinase by Modifying the Adaptor STING,”
[cited by applicant]
Zhang et al., “The Cytosolic DNA Sensor cGAS Forms an Oligomeric Complex with DNA and Undergoes Switch-like Conformational Changes in the Activation Loop,”
[cited by applicant]
Nielsen et al., “Therapeutic efficacy of anti-ErbB2 Immunoliposomes targeted by a phage antibody selected for cellular endocytosis,”
[cited by applicant]
Ohki-Hamazaki, et al., “Development and Function of Bombesin-Like Peptides and Their Receptors,” Int. J. Dev. Biol., vol. 49, pp. 293-300 (2005).
[cited by applicant]
Sagnella et al., “Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma,”
[cited by applicant]
Sharma et al., “Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy,”
[cited by applicant]
Showalter, Cytokines in Immunogenic Cell Death: Applications for Cancer Immunotherapy,
[cited by applicant]
Sun, et al., “Overexpression of Bcl2 Blocks TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in Human Lung Cancer Cells,” Biochemical and Biophysical Research Communications, vol. 280, No. 3, pp. 788-797 …
[cited by applicant]
Sun et al., “Cyclic GMP-AMP Synthase is a Cytosolic DNA Sensor that Activates the Type-I Interferon Pathway,”
[cited by applicant]
Sun, et al., “Peptide based imaging agents for cancer detection,” Adv. Drug Deliv. Rev., vol. 110-111, pp. 38-51 (2017).
[cited by applicant]
Szkandera et al., “Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients,” British Journal of Cancer, vol. 110, pp. 183-188 (2014).
[cited by applicant]
Takahashi, et al., “Imaging surface immobilization chemistry: correlation with cell patterning on non-adhesive hydrogel thin films,” Adv Funct Mater, vol. 18, pp. 2079-2088 (2008).
[cited by applicant]
Takaoka et al., “DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response,” Nature, 448, pp. 501-505 (2007).
[cited by applicant]
Takeshita et al., “Systemic Delivery of Synthetic MicroRNA-16 Inhibits the Growth of Metastatic Prostate Tumors via Downregulation of Multiple Cell-cycle Genes,” Molec. Ther., vol. 18, pp. 181-187 (2010).
[cited by applicant]
Tatemoto, et al., Neuropeptide Y: history and overview, Neuropeptide Y and Related Peptides. Springer; pp. 1-21 (2004).
[cited by applicant]
Teunissen et al., “Peptide receptor radionuclide therapy,” Best Pract Res Clin Gastroenterol., vol. 9(4), pp. 595-616 (2005).
[cited by applicant]
Tyler-McMahon, et al., “Neurotensin: peptide for the next millennium,” Regul. Pept., vol. 93, pp. 125-136 (2000).
[cited by applicant]
Unterholzner, “The interferon response to intracellular DNA: why so many receptors?”, Immunobiology, vol. 218(11), pp. 1312-1321 (Nov. 2013).
[cited by applicant]
Van Zandwijk et al., “Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study,” Lancet Oncol., 18(10), pp. 1…
[cited by applicant]
Ventola, “Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Consierations,” Pharmacy and Therapeutics, vol. 42, pp. 452-463 (2017).
[cited by applicant]
Search Report issued in co-pending European Patent Application No. 19839892.7, dated Mar. 7, 2022.
[cited by applicant]
Solomon et al., A First-Time-in-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells, PLOS One, 17 pages (Dec. 2015).
[cited by applicant]
Bograd, et al., “Immune Responses and Immunotherapeutic Interventions in Malignant Pleural Mesothelioma,”
[cited by applicant]
Schneiders, et al., “Clinical Experience with a-galactosylceramide (KRN7000) in Patients with Advanced Cancer and Chronic Hepatitis B/C Infection,” Clinical Immunology, vol. 140, pp. 130-131 (2011).
[cited by applicant]
Liang, et al., MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3, Molecular Cancer, vol. 14, No. 58, pp. 1-13 (2015).
[cited by applicant]
Office Action with Search Report for Chinese Patent Application No. 2019800601856, dated Nov. 29, 2023.
[cited by applicant]
Notice of Reasons for Refusal issued in Japanese Patent Application No. 2023-222336, dated Jan. 21, 2025.
[cited by applicant]
Decision of Rejection issued in Japanese Patent Application No. 2023-222336 dated Jul. 1, 2025 (7 pages with English language translation).
[cited by applicant]